Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

Inclusion Criteria: * Aged from 18 to 65 years. * Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO classification) : * Diffuse large B cell lymphoma. * Adverse prognostic factors IPI\>1 * In Complete Remission, or partial response to first line treatment. * Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP * Chemo-sensitive disease * PET Scan prior transplant * Eligible for autologous stem cell transplantation * With a minimum life expectancy of 3 months. * Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination). * Having previously signed a written informed consent. Exclusion Criteria: * Histological transformation in diffuse large B cell lymphoma, any type of low grade lymphoma * More than one line of treatment. Prior transplantation. Prior exposure to Zevalin * Central nervous system or meningeal involvement by lymphoma. * Contraindication to any drug contained in the chemotherapy regimen. * Any serious active disease or co-morbid medical condition (according to the investigator's decision and information provided in the IDB). * Poor renal function (creatinin level up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less than 100 G/l * Large bone marrow irradiation more than 40percent. * Bone marrow infiltration * Lack of sufficient autologous hematopoietic stem cells for transplantation. * Prior treatment with murine antibodies * Known hypersensibility to murine antibodies or proteins * Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Adult patient unable to give informed consent because of intellectual impairment. * Pregnant or lactating women.